SR One Capital Management LP acquired a new position in shares of enGene Holdings Inc. (NASDAQ:ENGN – Free Report) in the second quarter, HoldingsChannel.com reports. The fund acquired 500,000 shares of the company’s stock, valued at approximately $4,715,000. enGene makes up about 1.5% of SR One Capital Management LP’s holdings, making the stock its 8th largest position.
Several other hedge funds also recently made changes to their positions in ENGN. Altitude Crest Partners Inc. acquired a new stake in shares of enGene in the 1st quarter valued at approximately $2,039,000. Janus Henderson Group PLC acquired a new stake in shares of enGene in the first quarter valued at about $17,095,000. Omega Fund Management LLC purchased a new stake in enGene during the fourth quarter worth about $10,441,000. Finally, BVF Inc. IL purchased a new stake in enGene during the fourth quarter worth about $20,777,000. Institutional investors and hedge funds own 64.16% of the company’s stock.
enGene Price Performance
enGene stock opened at $7.21 on Friday. The firm’s 50-day moving average is $7.30 and its two-hundred day moving average is $11.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 42.80. The stock has a market capitalization of $318.44 million, a P/E ratio of -4.34 and a beta of -0.67. enGene Holdings Inc. has a 12-month low of $4.94 and a 12-month high of $43.00.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the company. Oppenheimer began coverage on enGene in a research note on Wednesday, August 28th. They issued an “outperform” rating and a $30.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $33.67.
View Our Latest Stock Analysis on ENGN
enGene Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 9/16 – 9/20
- Most active stocks: Dollar volume vs share volume
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN – Free Report).
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.